MEDICEN France

Are you seeking to develop your R&D skills, enhance your innovation potential and increase your business opportunities ? Check how Medicen Paris Region can help you.

Ms Béatrice Falise-Mirat
CEO 

Medissimo France

Medissimo Medissimo offers tools for preparation of prebscription (pillboxes) with full traceability Industry sectors Other: Health and tr Therapeutics Area Adherence
Your innovative solution

imedipac is a connceted, rec hageable, pillbox for better treatment adhrence

Which problem are you solving ?

imedipac's main objective is to increase treatment adherence and measure it 

Target market segments

Patients at home/patients in nursing homes

Key value proposition

Well designed connected pillbox/reliability/total traceability/very good knowledge of our market in France

Caroline Blochet
Presidente 

MedMira United States

Built on our patented Rapid Vertical Flow Technology™, MedMira rapid tests provide fast, accurate results. Features:
  • 3-step procedure
  • Instant results
  • Whole blood, serum or plasma specimens
  • Up to 24 month shelf-life at 2 – 30° C
  • Compact, single-use, 1.28 oz. package
  • No refrigeration required
  • Built-in procedural and reagent control line
  • Standardized procedure across all products
Dr Kevin Jones
Head of Commercialization 

Memorial Sloan-Kettering Cancer Center United States

​LinkedIn Profile

http://www.linkedin.com/pub/hayden-y-t-huang/22/227/913

Hayden Yao-Ting Huang PhD, MPH
Principal Investigator: Patients Engagement in Clinical Trials. Co-Principal Investigator: Infections Burden on Cancer Patients 

Memorial Sloan-Kettering Cancer Center United States

Memorial Sloan Kettering Cancer Center — the world’s oldest and largest private cancer center — has devoted more than 130 years to exceptional patient care, innovative research, and outstanding educational programs. Today, we are one of 45 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment.

The close collaboration between our physicians and scientists is one of our unique strengths, enabling us to provide patients with the best care available as we work to discover more-effective strategies to prevent, control, and ultimately cure cancer in the future. Our education programs train future physicians and scientists, and the knowledge and experience they gain at Memorial Sloan Kettering has an impact on cancer treatment and biomedical research around the world.

Learn more about Memorial Sloan Kettering.

Mr Jonathan Walland
Associate General Counsel 

Mercadyne Investments LLC United States

Mercadyne Advisors LLC advises private and public companies regarding capital strategy, business strategy, board governance, and restructuring. 

Mercadyne enables public companies to maximize shareholder value by positioning the company’s capitalization, Board and enterprise such that Wall Street will reward them for their business. 

Mercadyne also provides private companies seeking capital and liquidity an alternative financing path to the conventional, strict venture capital-to-large IPO process. We provide these emerging growth companies with an alternative public offering (APO) or direct public offering (DPO), structure via a public vehicle or small IPO (SIPO) strategy.

Robert Smith
Portfolio Manager 

Merck United States

Merck United States

From developing new therapies that treat and prevent disease to helping people in need, we're committed to improving health and well-being around the world.
Dr Luther T. Clark
Global Director, Scientific, Medical and Patient Perspective 

MERCK United States

From developing new therapies that treat and prevent disease to helping people in need, we're committed to improving health and well-being around the world.
Dr Ramesh Kashi
Senior Principal Scientist 

MERCK & Co United States

Mr Jaime Melendez
Associate Director, Technology Partnership and Business Development